Reed is former Senior Vice President, U.S. Sales and Sales Training, at Allergan Aesthetics at Abbvie
Tod Reed will join Lynch Regenerative Medicine, LLC (LRM) as a Senior Strategic Advisor. Reed recently retired as the Senior Vice President, U.S. Sales and Sales Training, at Allergan Aesthetics, an Abbvie company.
Reed brings 37 years of experience with Allergan to the LRM team, including more than 20 years in aesthetic and regenerative medicine. During his tenure at Allergan Aesthetics, Reed was responsible for helping build the largest sales organization in U.S. medical aesthetics while helping launch iconic brands such as Botox Cosmetic®, Juvederm®, and many other products in skin care, body contouring and aesthetic surgery. He was also responsible in the U.S. market for the renowned practice consulting group, strategic accounts, sales force operations and the sales training department.
“At LRM, we are building a leading regenerative medicine and aesthetics company based on the most proven and trusted science in the industry, combined with the some of the most experienced, talented and trusted people in aesthetics and regenerative medicine,” said Dr. Samuel Lynch, founder and CEO of LRM. “Tod’s leadership at Allergan Aesthetics helped build it into the world’s largest aesthetic medicine company. We welcome him to the LRM team, where we strive every day to bring the best products together with the best people to advance the regenerative medicine and aesthetics fields.”
“I am humbled and excited to join Lynch Regenerative Medicine as a strategic advisor,” said Reed. “The team is excellent, with years of industry experience, and the product line both current and in the future will bring needed enhancements to the growing markets for aesthetics and regenerative medicine.”
LRM’s first product to improve skin aesthetics, Ariessence™ Pure PDGF+ (www.ariessence.com), is available in leading innovative med/spa clinics and other aesthetic-focused offices, including dermatology and plastic surgery practices. Ariessence Pure PDGF+ is used topically to improve aesthetic outcomes associated with procedures such as micro-needling, dermabrasion, lasers, plastic surgery and other procedures in which healthier-looking skin can be accelerated and enhanced using growth factors such as PDGF.
“Growth factors play an important role in skin care today, but no other solutions are backed by the high level of scientific and clinical evidence that supports the safety and effectiveness of pure PDGF in multiple regenerative treatments,” said Lynch. “Ariessence Pure PDGF+ is based on this foundation of success in regenerative medicine.”
About Lynch Regenerative Medicine, LLC
Lynch Regenerative Medicine, LLC is pioneering innovative treatments that aim to revolutionize the $100 billion aesthetics and wound-care markets. Our mission is to leverage our regenerative medicine heritage and our decades-long commitment to safe and effective regenerative products of the highest quality to deliver exceptional results for our customers and their patients, thereby redefining the future of aesthetic regenerative medicine. The company was founded in 2023 and is based in Franklin, Tennessee.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240814002316/en/
Contacts
Nancy Rocco, n.rocco@lynchregen.com; 888-576-7343